This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2001;119:300-301.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Latanoprost is a phenyl-substituted isopropyl ester of prostaglandin F₂ that enhances uveoscleral outflow and lowers intraocular pressure. Its potency, once-daily dosing schedule, and low incidence of adverse effects led to widespread use immediately after its release in the United States. Since then, adverse effects such as anterior uveitis and cystoid macular edema¹ have been reported. This report describes 3 patients who experienced new onset of migraine headache after taking latanoprost; 2 patients had to discontinue the drug. This adverse effect previously has not been reported in association with latanoprost use. The trigeminovascular theory of migraine pathogenesis could explain this association.

Report of Cases

Case 1

A 65-year-old man with primary open-angle glaucoma that was previously well controlled with topical therapy became allergic to dipivefrin hydrochloride and dorzolamide hydrochloride. He was intolerant of -blockers because of a cardiac arrhythmia. He was prescribed latanoprost for both eyes at bedtime. Although the patient had no prior history of . . . [Full Text of this Article]

Case 2

Case 3

Comment
Corresponding author and reprints: Bonnie C. Weston, MD, FRCSC, Department of Ophthalmology, University of South Alabama, HSB Room 2500, 307 University Blvd, Mobile, AL 36688.